- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04433325
COVID-19 Critically Ill Patients' Evolution After Medical Transport by Train From Paris Intensive Care Units to West of France Intensive Care Units (TOCCIP)
June 15, 2020 updated by: Rennes University Hospital
Since early 2020, France knows a sanitary crisis with a massive influx of COVID-19 patients admitted in Intensive Care Units (ICU).
It led to a saturation of the French health system, especially in some geographic areas such as East of France or Paris region.
Therefore, authorities decided to transfer some critically ill patients from these crowded ICUs to less busy regional ICUs. it was done for the first time by medical train transportation.
Knowing that the investigators lack experience regarding this type of medical evacuation, regarding the high number of transferred patients, with such a logistic effort, the investigators decided to study this phase of the COVID-19 sanitary crisis in order to draw a feedback.
So far, there are no data in the literature regarding this topic.
Study Overview
Status
Unknown
Conditions
Study Type
Observational
Enrollment (Anticipated)
150
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Nicolas Mevel
- Phone Number: 0299282555
- Email: dri@chu-rennes.fr
Study Contact Backup
- Name: Anne Ganivet
- Phone Number: 0299282555
- Email: anne.ganivet@chu-rennes.fr
Study Locations
-
-
-
Poitiers, France
- CHU Poitiers
-
Contact:
- Arnaud THILLES
-
Tours, France
- CHU Tours
-
Contact:
- Stéphane ERHMANN
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
COVID-19 positive patients admitted in Intensive Care Unit between 15/03/2020 and 15/04/2020
Description
Inclusion Criteria:
- Age > 18 years
- COVID-19 positive patients admitted in Intensive Care Unit between 15/03/2020 and 15/04/2020
- Patients (or legal representative) with no opposition to inclusion in medical research protocol
- Regarding case group : Patients transferred from Paris's ICU
- Regarding case control group : Patients admitted in ICU with no transfer from Paris
Exclusion Criteria:
- > 18 years under legal protection and patients with liberty restriction
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
---|
Patients transferred
Patients transferred from Paris's Intensive Care Units
|
Patients not transferred
Patients admitted in Intensive Care Units with no transfer from Paris
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
number of death
Time Frame: at Intensive Care Units discharge, an average of 1 months
|
to evaluate mortality
|
at Intensive Care Units discharge, an average of 1 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
number of infections
Time Frame: from date of admission until Intensive Care Units discharge, assessed up to 1 months
|
to evaluate morbidity
|
from date of admission until Intensive Care Units discharge, assessed up to 1 months
|
number of days of mechanical ventilation
Time Frame: from date of admission until Intensive Care Units discharge, assessed up to 1 months
|
from date of admission until Intensive Care Units discharge, assessed up to 1 months
|
|
number of days of sedation
Time Frame: from date of admission until Intensive Care Units discharge, assessed up to 1 months
|
from date of admission until Intensive Care Units discharge, assessed up to 1 months
|
|
number of days of use of neuromuscular blocking agents
Time Frame: from date of admission until Intensive Care Units discharge, assessed up to 1 months
|
from date of admission until Intensive Care Units discharge, assessed up to 1 months
|
|
number of days of vasopressor use
Time Frame: from date of admission until Intensive Care Units discharge, assessed up to 1 months
|
from date of admission until Intensive Care Units discharge, assessed up to 1 months
|
|
number of days in Intensive Care Units
Time Frame: from date of admission until Intensive Care Units discharge, assessed up to 1 months
|
from date of admission until Intensive Care Units discharge, assessed up to 1 months
|
|
number of days in hospital
Time Frame: from date of admission until hospital discharge, assessed up to 1 months
|
from date of admission until hospital discharge, assessed up to 1 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Benoît Painvin, CHU Rennes
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
June 1, 2020
Primary Completion (Anticipated)
July 1, 2020
Study Completion (Anticipated)
September 1, 2020
Study Registration Dates
First Submitted
June 12, 2020
First Submitted That Met QC Criteria
June 15, 2020
First Posted (Actual)
June 16, 2020
Study Record Updates
Last Update Posted (Actual)
June 16, 2020
Last Update Submitted That Met QC Criteria
June 15, 2020
Last Verified
June 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 35RC20_3091_TOCCIP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece